Navigation Links
S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
Date:12/12/2011

nts.  At the six-month visit, a significant reduction (>2 point improvement in mean symptom score) was observed for MF-associated symptoms, including abdominal pain, bone pain, early satiety, worst fatigue, inactivity, night sweats and pruritus.

"There is a significant medical need in the treatment of myelofibrosis and the results from pacritinib's clinical trials encourage us to quickly move forward with a global Phase 3 study to further demonstrate pacritinib's clinical benefits and consequently capture an important niche market in the treatment of MF," said Tamar Howson, interim CEO and board member of S*BIO.

Pacritinib is a small molecule JAK2-selective kinase inhibitor, which has demonstrated high potency in preclinical models against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in myeloproliferative disorders such as MF. It is estimated that approximately 50% of patients with MF possess the JAK2 mutation.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs including kinases and histone deacetylases (HDAC). Pacritinib, or SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has completed Phase 2 trials for MF. It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, pracinostat (SB939), is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and o
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. University Hospitals Seidman Cancer Center Tests Novel Drug That Makes Brain Tumors Glow Hot Pink
2. Novelos Therapeutics Prices $5.9 Million Public Offering
3. MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
4. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
5. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
6. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
7. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
8. CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
9. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
10. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
11. Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Inc. (NYSE: PFE ) today announced ... Innovation, an entrepreneurial network of partnerships with leading ... by accessing leading translational researchers.  The University of ... the network. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... 16, 2010 Baxa Corporation , a leading ... operations, today announced significant upgrades to its DoseEdge ... workflow management tool that verifies the use of correct ... chemo, TPN and oral liquid doses.  This release includes ...
Cached Medicine Technology:Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 2Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 3Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 4Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 2Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 3Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 4
(Date:8/29/2014)... The Department of Health and Human Services (HHS) ... today allowing healthcare providers to attest for Meaningful Use ... (CEHRT) or a combination of the 2011 and 2014 ... able to fully implement 2014 Edition CEHRT for a ... use 2011 Edition CEHRT, or a combination of 2011/2014 ...
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... has announced his plan to rename his practice to ... US Hair Restoration has served the needs of hair ... clients who traveled to its centers in Los Angeles, ... results through surgical and non surgical treatments, many of ...
(Date:8/29/2014)... 30, 2014 UWDress.com, one of the ... its latest collection of 2014 floor length bridesmaid ... for these wonderful items. According to the company’s marketing ... a greatly discounted rate (up to 60 percent off) ... products has a special neckline: strapless, one-shoulder, bateau and ...
(Date:8/29/2014)... 2014 As reported by GantDaily.com in the ... Abuse Trends , Outbreaks (8/20), the National Institute on Drug ... drug abuse trends by turning to social media. As NIDA ... it is also working with the University of Maryland to ... Warning System, which will be funded by the National Institute ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
Breaking Medicine News(10 mins):Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... Based on findings of a recent study researchers say eating ... Researchers say they have found a correlation between high consumption ... hot dogs, and lunch meats like ham, salami and bologna, ... study, nearly 149,000 meat eaters between ages 50 and 74 ...
... part of the body’s immune system and help protect ... A new study shows promising treatment for acute myelogenous ... natural killer cells from a patient’s family member. ... the highly fatal cancer of the bone marrow that ...
... study researchers say autistic boys with language problems might have ... disorder known as Specific Language Impairment (SLI) // and they ... and how to choose the best treatments for individual components ... at Broca’s area -- a key language center in the ...
... as a man’s disease, but recent reports suggest it ... is helping to identify which women are at highest ... records of nearly 2,400 women taking part in the ... heart disease are about three-times more likely to develop ...
... New research shows that people who have implanted ... safely use magnetic resonance imaging .// ,Pacemakers ... regulate an abnormal heartbeat known as arrhythmia. Researchers ... of the MRI may heat up metal components ...
... gene known as “mighty mouse” might be beneficial in ... a German neurologist , stumbled // on a newborn who ... child had a mutation in his myostatin gene that effectively ... known to regulate muscle growth. So far the child, now ...
Cached Medicine News:
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... is the first microplate spectrophotometer designed specifically ... days per week. With rugged hardware, proven ... breaks the barrier of traditional spectrophotometry to ... instrument can easily read up to eight, ...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
Medicine Products: